Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life

INTRODUCTION: In 2017, all people with severe hemophilia B in Ireland switched to recombinant factor IX Fc fusion protein concentrate (rFIXFc) prophylaxis. Patient‐reported outcomes (PROs) and health‐related quality of life (HRQoL) are important to evaluate with new treatments. AIMS: To assess HRQoL...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Donovan, Mairead, Quinn, Eimear, Johnston, Kate, Singleton, Evelyn, Benson, Julie, O'Mahony, Brian, Noone, Declan, Duggan, Cleona, Gilmore, Ruth, Ryan, Kevin, O'Donnell, James S., O’Connell, Niamh M., Mahlangu, Johnny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505226/
https://www.ncbi.nlm.nih.gov/pubmed/34667923
http://dx.doi.org/10.1002/rth2.12602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505226/
https://www.ncbi.nlm.nih.gov/pubmed/34667923
http://dx.doi.org/10.1002/rth2.12602

Ejemplares similares